IP Considerations Following FDA Announcement on Flexibility for Cell and Gene Therapies
Key Takeaways: Manufacturing processes of cell and gene therapies (CGTs) may remain fluid well into development and even after FDA approval, and therefore sponsors of CGTs may benefit from patent...
Is Your IP Ready? Navigating IP Challenges for Commercial-Stage Technologies in Due Diligence and M&A
Presenting as part of an LSI ’26 panel, Knobbe Martens partners Kregg Koch and Sabing Lee joined fellow panelists to explore the complexities of intellectual property management for commercial-stage technologies in the medtech industry, and the...
Charlene Azema and Sheila Swaroop Shortlisted for 2026 Women in Business Law Awards
IRVINE, Calif., April 2, 2026 – Knobbe Martens is pleased to share that partners Charlene Azema and Sheila Swaroop have been shortlisted for the 2026 Women in Business Law Americas...
Subscribe for News and Updates